An agentic platform for life sciences In beta
Your main agent coordinates specialist subagents for scientific research and business analysis. They search source databases, run code in R and Python, and write reports with citations. You review the results and working files in one canvas.
Examine an asset, a deal or a portfolio with its scientific evidence and business assumptions together. Use the analyses that fit your question.
Explore decision analysesFor biotech and pharma teams, technology-transfer offices, consultants and investors. Decision support, with judgment and approval remaining with you.
What is the opportunity worth, and on what terms?
Connect development risk, cost, timing and commercial assumptions to value. Examine the effect of upfront payments, milestones and royalties instead of treating the headline valuation as the answer.
rNPV · Monte Carlo scenarios · Sensitivity analysis · Deal assumptions
Which programs deserve the next commitment?
Compare opportunities against cash, capacity and strategic priorities. Explore shared scientific risk, diversification and the consequences of advancing, delaying or partnering a program.
Allocation options · Risk and correlation · Budget constraints · Sequencing
Where should an asset go next?
Bring disease biology, unmet need, clinical feasibility, differentiation and economics into the same assessment. Keep evidence gaps visible when comparing indications and development paths.
Indication comparisons · Target product profiles · Patient funnels · Development options
Where can this program compete?
Understand competitors, clinical readouts, standards of care and emerging technologies. Examine how a new result or market development changes the positioning of an asset or platform.
Competitive landscapes · Trial comparisons · Market context · Catalyst monitoring
How could a discovery become a development opportunity?
Explore applications for a technology, map patent and competitive evidence, and research potential partners. Build an opportunity brief that makes both the promise and the outstanding work clear.
Application assessments · Patent landscapes · Partner research · Commercialization briefs
What would strengthen, weaken or stop the case?
Investigate scientific, clinical, IP and commercial assumptions together. Compare an asset, pipeline or platform with alternatives, and prepare the unresolved questions for expert and investment review.
Evidence and risk maps · Scenario comparisons · Diligence questions · Decision memos
A headline value is only a starting point. Inspect the assumptions, downside and alternatives. Compare what the science supports with what the economics require.
Evidence stays visible. Trace the premise back to its sources and keep contradictory findings in view.
Assumptions stay explicit. Review probability, timing, cost, revenue and constraints before relying on an output.
Uncertainty stays in the case. Compare scenarios and missing evidence instead of treating one estimate as certainty.
Bring your experimental files and the question you want to test. ARiDA prepares and runs an analysis, then helps you interpret it against the literature and biological databases.
Choose a method, or describe the study and ask ARiDA to help select one.
Bulk RNA-seq · Single-cell RNA-seq · Spatial transcriptomics
Fit expression contrasts, compare conditions by biological sample and examine spatial patterns.
Chromatin accessibility · DNA methylation · Variant & cancer genomics · Statistical genetics
Assess differential accessibility or methylation, inspect variants and run association, fine-mapping or colocalization analyses.
Proteomics · Metabolomics · Microbiome analysis
Compare measured abundances, inspect sample quality and analyze microbial diversity.
Bioinformatics analysis · Sequencing read processing · Phylogenetic analysis
Choose a method for your files, check and prepare reads, or align sequences and infer evolutionary trees.
Other research methods cover assay QC and dose-response, PK, biochemical kinetics, microscopy, statistical and survival analysis, pathway enrichment, cheminformatics and structural biology.
Run a packaged method or adapt the code to your study. The environment supports compatible libraries and document tools for lab reports, manuscript drafts and presentations.
Large whole-genome pipelines, GPU work and very large datasets need suitable external compute.
In Free-flow, your main agent scopes the task and delegates work as needed. Independent tasks can run in parallel; you can change direction while the investigation is underway.
Bring files, choose a method or describe the result you need. Tell the main agent when the scope changes.
Call on literature, biological-database, SQL, web, clinical, patent, regulatory and grant specialists, with separate agents for data analysis, valuation and writing.
Open the tables, code and reports in the canvas. Ask for a revision or resume a specialist with a follow-up; the working files remain with the conversation.
For example, a literature specialist can collect papers while the analysis agent works on your dataset. Once their work is ready, a writer can prepare a report with citations to the sources and results.
For a defined study, use a methodology with explicit inputs, assumptions and output checks. Studios complement open-ended work; they do not prescribe how every question must be approached.
Explore the StudiosDoes this target deserve the next investment?
Assemble target identity, disease biology, mechanism, tractability, safety and clinical precedent. ARiDA shows which evidence strengthens the thesis, which evidence blocks it and what should be learned next.
Target evidence and contradiction mapShould this asset advance, defer, stop, be licensed or be passed?
Keep molecular developability, mechanism, clinical evidence, safety, competitive analogues, regulatory context, IP evidence and business assumptions inside the same asset case.
Asset 360 decision caseWhere should this asset go next?
Compare scientific admissibility, clinical feasibility, differentiation, economics and execution constraints without hiding a weak dimension inside one composite score.
Admissible indication shortlistWhat is the defensible value range, and what moves it?
Connect scientific and clinical assumptions to rNPV, Monte Carlo distributions, real options and value of information. Reviewers can inspect an assumption and rerun the affected case.
Risk-adjusted value distributionWhich programs should receive capital now?
Evaluate assets against strategy, cash, capacity, shared scientific risk, timing and available options. Keep credible alternatives and dominated choices visible for the committee.
Portfolio risk and correlation viewWhich IP evidence changes the business decision?
Connect patent-family, ownership, claim-theme, exclusivity and proceeding evidence to lifecycle, transaction and competitive questions. Patent Studio prepares evidence for business and counsel review. It does not provide legal opinions or clearance conclusions.
Patent-family and ownership mapFollow a target from biological evidence to trials, patents and company activity. Database tools, web research and your own files supply different parts of that investigation.
Evidence sources by topic: Targets: Open Targets · UniProt · NCBI Gene; Drugs: ChEMBL · PubChem · openFDA; Compounds & assays: ChEMBL · PubChem · your data; Clinical trials: ClinicalTrials.gov · AACT; Patents & IP: Google Patents · EPO · USPTO; Literature: PubMed · PubMed Central; Diseases & evidence: Open Targets · Ensembl; Companies & deals: SEC EDGAR · company reports.
Illustrative source relationships.
PubMed · PubMed Central
Literature toolsOpen Targets · NCBI Gene/Protein · UniProt · Ensembl · MyGene · HGNC · InterPro · EBI Proteins
Database tools & configured SQLRCSB PDB · PDBe · AlphaFold DB
Structure databasesReactome · STRING · Human Protein Atlas · OLS ontologies
Database toolsChEMBL · PubChem
Database tools & configured SQLClinicalTrials.gov · AACT
Registry tools & configured SQLGoogle Patents · EPO/INPADOC · USPTO/PTAB · SureChEMBL · BigQuery patent datasets · CourtListener
Patent tools & analyticsopenFDA · eCFR · Orange Book · Purple Book
Source tools; FDA, EMA & ICH documents via web researchNIH RePORTER · Grants.gov
Funding toolsSEC EDGAR · Company reports · Filings · News
SEC tools & web researchGEO processed matrices · ENA sequencing reads
Known-accession retrieval, not repository-wide searchUploaded papers, datasets & models · Library files · Google Drive · OneDrive · SharePoint
Uploads & permissioned connectionsSome sources need credentials or configured databases. Full-text access and connected files remain subject to permissions and licensing.
Move from the working analysis to a research report, client presentation or decision brief. These are actual files made with scientific and document tools available in ARiDA.
Fitted curves, readable axes and the method behind the numbers. Keep the figure and the analysis that produced it.
PNG · analysis data · code
Dose-response analysis · synthetic assay data
Scientific examples use synthetic data. The clinical comparison uses trial registry records.
Set up recurring research, follow trial readouts or keep track of competitors and patent activity. Receive the update, ask what it means and return to the underlying work.
The full canvas and working files.
Scheduled briefings and follow-up questions.
A conversation you can continue on the move.
Updates in the place your team works.
Useful decision support makes the reasoning available for challenge. It does not remove the need for scientific, financial or legal judgment.
Model-provider privacy. Our standard Fireworks inference uses zero data retention and does not use your prompts or responses for model training. ARiDA saves your chats and files separately so you can return to your work.
Supported by
Ecosystem and memberships
Yes. Work can range from a literature question or dataset analysis to a competitive landscape, indication assessment, valuation or portfolio comparison. Researchers, TTOs, consultants, biotech and pharma teams can use the same underlying workspace. You do not need to turn a research question into an investment case.
No. Free-flow lets you explore, bring files, change direction and ask follow-up questions. Reusable methods can guide a particular task. Governed Studios add defined inputs, calculations and review requirements for supported studies; they are an option, not a prerequisite for using ARiDA.
Free-flow is an open-ended conversation with tools, specialist agents and a persistent canvas. A Studio applies a defined methodology to a particular scientific or business question, with explicit assumptions, evidence requirements and output checks. Studio availability depends on the beta configuration and the inputs required for the study.
Yes. Upload supporting files and work with them alongside available sources. ARiDA can write and run analysis code, create editable documents and retain the working files. Use material you have permission to process, and discuss data handling and access requirements with us before uploading sensitive information.
Inspect the sources, code, assumptions and working files behind an output. Bibliographic and report-writing checks help catch invalid references and citation inconsistencies. Governed studies add methodology-specific validation.
No. ARiDA supports the analysis and preparation behind a decision. Your team remains responsible for the assumptions, interpretation and approval. Patent research prepares evidence and questions for qualified counsel; it is not a legal opinion or a clearance conclusion.
Request access and tell us what you would like to work on. We will follow up by email to discuss access and the capabilities relevant to your work. Existing users can sign in directly.
ARiDA is in beta.
A scientific study, a client brief, an asset or a strategic decision. Let’s explore how ARiDA can help.
